Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.
02 Septiembre 2021 - 3:20PM
Reflecting continued clinical progress, Cellect Biotechnology Ltd.
(NASDAQ: “APOP”), announced the first ApoGraftTM transplantation in
a Leukemia patient in the Company’s clinical trial at Washington
University in the U.S. ApoGraftTM is a product based on the
Company’s cell selection technology designed to optimize immune
therapy, in this application - prevent graft-versus-host disease
(GVHD) following bone marrow transplantation.
Following the closing of the previously
announced strategic merger transaction between Cellect and Quoin
Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX,
the privately held U.S. based company that is acquiring Cellect’s
proprietary technology concurrently with such merger. The trial
will enroll 18 patients with hematological malignancies who are
undergoing a haploidentical Bone Marrow Transplantation (BMT).
EnCellX, led by Founder and CEO Adi Mohanty, is raising funds from
leading healthcare institutional investors to expedite and expand
clinical development.
“This is an important milestone for Cellect and
demonstrates the team’s professionalism and dedication for getting
us to this occasion,” commented Dr. Shai Yarkoni, Chief Executive
officer. “We look forward to working closely with EnCellX as its
U.S. based team will work closely with Washington University to
continue patient enrollment. This achievement, following the
release of positive topline data from the Israeli ApoGraftTM trial,
is timely as EnCellX is seeking to strengthen its balance sheet in
the near term to fund continuing clinical development.”
About Cellect Biotechnology
Ltd.
Cellect Biotechnology (APOP) has developed a
breakthrough technology, for the selection of stem cells from any
given tissue, that aims to improve a variety of cell-based
therapies.
The Company’s technology is expected to provide
researchers, clinical community, and pharma companies with the
tools to rapidly isolate specific cells in quantity and quality
allowing cell-based treatments and procedures in a wide variety of
applications in regenerative medicine. The Company’s current
clinical trial is aimed at bone marrow transplantations in cancer
treatment. Forward Looking
Statements
This press release contains forward-looking
statements about the Company’s expectations, beliefs and
intentions. Forward-looking statements can be identified by the use
of forward-looking words such as “believe”, “expect”, “intend”,
“plan”, “may”, “should”, “could”, “might”, “seek”, “target”,
“will”, “project”, “forecast”, “continue” or “anticipate” or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. For example, forward-looking statements are
used in this press release when we discuss Cellect’s expectations
regarding its U.S. clinical trial. These forward-looking statements
and their implications are based on the current expectations of the
management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
In addition, historical results or conclusions from scientific
research and clinical studies do not guarantee that future results
would suggest similar conclusions or that historical results
referred to herein would be interpreted similarly in light of
additional research or otherwise. The following factors, among
others, could cause actual results to differ materially from those
described in the forward-looking statements: the Company’s history
of losses and needs for additional capital to fund its operations
and its inability to obtain additional capital on acceptable terms,
or at all; the Company’s ability to continue as a going concern;
uncertainties of cash flows and inability to meet working capital
needs; the Company’s ability to obtain regulatory approvals; the
Company’s ability to obtain favorable pre-clinical and clinical
trial results; the Company’s technology may not be validated and
its methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company’s clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company’s ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company’s industry; unforeseen scientific difficulties may
develop with the Company’s technology; the Company’s ability to
retain or attract key employees whose knowledge is essential to the
development of its products; and the Company’s ability to pursue
any strategic transaction or that any transaction, if pursued, will
be completed. Any forward-looking statement in this press release
speaks only as of the date of this press release. The Company
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading “Risk Factors” in Cellect Biotechnology Ltd.’s Annual
Report on Form 20-F for the fiscal year ended December 31, 2020
filed with the U.S. Securities and Exchange Commission, or SEC,
which is available on the SEC’s website, www.sec.gov, and in the
Company’s periodic filings with the SEC.
ContactCellect Biotechnology
Ltd.Yaron Ben-Oz, Chief Financial
Officerwww.cellect.co+972-9-974-1444
Or
EVC Group LLCMichael Polyviou(732)
933-2754mpolyviou@evcgroup.com
Cellect Biotechnology (NASDAQ:APOP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Cellect Biotechnology (NASDAQ:APOP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024